Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration

Journal of the Neurological Sciences

Volumn 270, Issue 1-2, 2008, Pages 94-98

  Gaig, Carles ^a   Ezquerra, Mario ^a   Martí, Maria José ^a   Valldeoriola, Francesc ^a   Muñoz, Esteban ^a   Lladó, Albert ^a   Rey, Maria Jesús ^b   Cardozo, Adriana ^b   Molinuevo, José Luis ^a   Tolosa, Eduardo ^a  

^a Institut Clínic de Neurociències ICN   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Dementia with Lewy bodies; Frontotemporal lobar degeneration; LRRK2 G2019S mutation; LRRK2 R1441G mutation; Neuropathology; Non specific nigral degeneration; Parkinson's disease

Indexed keywords

SYNUCLEIN; TAU PROTEIN;

ADULT; ARTICLE; BRAIN DEGENERATION; BRAIN STEM; CODON; CORTICOBASAL DEGENERATION; DEMENTIA; FEMALE; FRONTOTEMPORAL LOBAR DEGENERATION; GENE MUTATION; GENETIC SCREENING; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PARKINSONISM; PATHOLOGY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SHY DRAGER SYNDROME; TAUOPATHY;

DEMENTIA; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GLYCINE; HUMANS; MALE; MUTATION; PARKINSONIAN DISORDERS; PROTEIN-SERINE-THREONINE KINASES; SERINE;

EID: 44449156412     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.02.010     Document Type: Article

References (33)

1. Paisán-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simón J., van der Brug M., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
2. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607
3. Gilks W.P., Abou-Sleiman P.M., Gandhi S., Jain S., Singleton A., Lees A.J., et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365 (2005) 415-416
4. Gaig C., Ezquerra M., Martí M.J., Muñoz E., Valldeoriola F., and Tolosa E. LRRK2 mutations in Spanish patients with Parkinson's disease: frequency, clinical features and incomplete penetrance. Arch Neurol 63 (2006) 377-382
5. Ross O.A., Toft M., Whittle A.J., Johnson J.L., Papapetropoulos S., Mash D.C., et al. LRRK2 and Lewy body disease. Ann Neurol 59 (2006) 388-393
6. Giasson B.I., Covy J.P., Bonini N.M., Hurtig H.I., Farrer M.J., Trojanowski J.Q., et al. Biochemical and pathological characterization of LRRK2. Ann Neurol 59 (2006) 315-322
7. Rajput A., Dickson D.W., Robinson C.A., Ross O.A., Dächsel J.C., Lincoln S.J., et al. LRRK2 G2019S, and tau neuropathology. Neurology 67 (2006) 1506-1508
8. Dächsel J.C., Ross O.A., Mata I.F., Kachergus J., Toft M., Cannon A., et al. LRRK2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. Acta Neuropathol 113 (2007) 601-606
9. Hughes A.J., Daniel S.E., Kilford L., and Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55 (1992) 181-184
10. Emre M., Aarsland D., Brown R., Burn D.J., Duyckaerts C., Mizuno Y., et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22 (2007) 1689-1707
11. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65 (2005) 1863-1872
12. Lladó A, Sánchez-Valle R, Rey MJ, Ezquerra M, Tolosa E, Ferrer I et al. Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration. J Neurol in press.
13. Litvan I., Hauw J.J., Bartko J.J., Lantos P.L., Daniel S.E., Horoupian D.S., et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 55 (1996) 97-105
14. Dickson D.W., Bergeron C., Chin S.S., Duyckaerts C., Horoupian D., Ikeda K., et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 61 (2002) 935-946
15. Gilman S., Low P.A., Quinn N., Albanese A., Ben-Shlomo Y., Fowler C.J., et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 163 (1999) 94-98
16. McKhann G.M., Albert M.S., Grossman M., Miller B., Dickson D., and Trojanowski J.Q. Report of the work group on frontotemporal dementia and Pick's disease. Clinical and pathological diagnosis of frontotemporal dementia. Arch Neurol 58 (2001) 1803-1809
17. Shi J., Shaw C.L., Du Plessis D., Richardson A.M., Bailey K.L., Julien C., et al. Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation. Acta Neuropathol 11 (2005) 501-512
18. Greggio E., Jain S., Kingsbury A., Bandopadhyay R., Lewis P., Kaganovich A., et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Aging 23 (2006) 329-341
19. Zhu X., Babar A., Siedlak S.L., Yang Q., Ito G., Iwatsubo T., et al. LRRK2 in Parkinson's disease and dementia with Lewy bodies. Mol Neurodegener 30 1 (2006) 17
20. Zhu X., Siedlak S.L., Smith M.A., Perry G., and Chen S.G. LRRK2 protein is a component of Lewy bodies. Ann Neurol 60 (2006) 617-618
21. Gaig C., Marti M.J., Ezquerra M., Rey M.J., Cardozo A., and Tolosa E. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J Neurol Neurosurg Psychiatry 78 (2007) 626-628
22. Ross O.A., Whittle A.J., Cobb S.A., Hulihan M.M., Lincoln S.J., Toft M., et al. Lrrk2 R1441 substitution and progressive supranuclear palsy. Neuropathol Appl Neurobiol 32 (2006) 23-25
23. Tan E.K., Skipper L., Chua E., Wong M.C., Pavanni R., Bonnard C., et al. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease. Mov Disord 21 (2006) 997-1001
24. Hernandez D., Paisan Ruiz C., Crawley A., Malkani R., Werner J., Gwinn-Hardy K., et al. The dardarin G2019S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci Lett 389 (2005) 137-139
25. Ozelius L.J., Foroud T., May S., Senthil G., Sandroni P., Low P.A., et al. G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord 22 (2007) 546-549
26. Chen-Plotkin A.S., Yuan W., Anderson C., Wood E.M., Hurtig H.I., Clark C.M., et al. Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology 70 7 (2008) 521-527
27. Infante J., Rodríguez E., Combarros O., Mateo I., Fontalba A., Pascual J., et al. LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease. Neurosci Lett 395 (2006) 224-226
28. Mata I.F., Taylor J.P., Kachergus J., Hulihan M., Huerta C., Lahoz C., et al. LRRK2 R1441G in Spanish patients with Parkinson's disease. Neurosci Lett 382 (2005) 309-311
29. Kimchi-Sarfaty C., Oh J.M., Kim I.W., Sauna Z.E., Calcagno A.M., Ambudkar S.V., et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315 (2007) 525-528
30. Toft M., Sando S.B., Melquist S., Ross O.A., White L.R., Aasly J.O., et al. LRRK2 mutations are not common in Alzheimer's disease. Mech Ageing Dev 126 (2005) 1201-1205
31. Haubenberger D., Bonelli S., Hotzy C., Leitner P., Lichtner P., Samal D., et al. A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease. Mov Disord 22 (2007) 1640-1643
32. Covy J.P., Van Deerlin V.M., and Giasson B.I. Lack of evidence for Lrrk2 in α-synuclein pathological inclusions. Ann Neurol 60 (2006) 618-619
33. Higashi S., Biskup S., West A.B., Trinkaus D., Dawson V.L., Faull R.L., et al. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res 1155 (2007) 208-219